A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

Status Completed

Clinical Trial Summary

To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.

Clinical Trial Description

Primary Objective:

The primary objective of this study is to identify whether frataxin levels and specific RNAs and proteins in blood and buccal cells differ between patients with FRDA and controls.

Secondary Objective:

The secondary objectives of this study are:

- To understand the variability of frataxin and specific RNAs and proteins identified in buccal cells.

- To correlate levels of frataxin and specific RNAs and proteins with features of FRDA.

- To correlate levels of frataxin and specific RNAs and proteins with triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL) levels, and other lipids. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04255680
Study type	Observational
Source	Larimar Therapeutics, Inc.
Contact
Status	Completed
Phase
Start date	January 14, 2020
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05573698` - Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia	Phase 1
Completed	`NCT00229632` - Idebenone to Treat Friedreich's Ataxia	Phase 2
Completed	`NCT05579691` - A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia	Phase 2
Completed	`NCT04273165` - Safety and Efficacy of Etravirine in Friedreich Ataxia Patients	Phase 2
Not yet recruiting	`NCT05874388` - Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia	N/A
Completed	`NCT02594917` - Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
Completed	`NCT01716221` - An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Phase 4
Active, not recruiting	`NCT05485987` - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia	Phase 2
Completed	`NCT03214588` - Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia	Phase 2
Completed	`NCT03418740` - Neurology Measures in FA Children
Not yet recruiting	`NCT06054893` - A Study of Omaveloxolone in Children With Friedreich's Ataxia	Phase 1
Recruiting	`NCT04921930` - Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)	Phase 1/Phase 2
Completed	`NCT03933163` - Micronised Resveratrol as a Treatment for Friedreich Ataxia	Phase 2
Completed	`NCT02705547` - Rosuvastatin (Crestor) in Friedreich Ataxia	Early Phase 1
Completed	`NCT02035020` - A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients	Phase 2
Completed	`NCT00015808` - Safety Study of Idebenone to Treat Friedreich's Ataxia	Phase 1
Completed	`NCT04817111` - NAD+ Precursor Supplementation in Friedreich's Ataxia	Phase 2
Active, not recruiting	`NCT05168774` - FRDA Investigator Initiated Study (IIS) With Elamipretide	Phase 1/Phase 2
Completed	`NCT03917225` - A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients	Phase 2
Completed	`NCT00224640` - Iron-Chelating Therapy and Friedreich Ataxia	Phase 1/Phase 2